Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Most important ASCO 2026 myeloma abstract.
Practice changing. Majestec-9 trial. PFS significantly better with Teclistmaab vs PVd/Kd (HR, 0.29; 95% CI, 0.23-0.38; P<0.0001); 18-mo PFS rate: 69.8% vs 26.9%.
OS significantly better with Tec vs PVd/Kd (HR, 0.60; 95% CI, 0.43-0.83; P=0.002)
Based on this, teclistamab now becomes the leading first choice along with ciltacel for relapsed myeloma in dara refractory patients.”
Other articles about Myeloma on OncoDaily.